Evidence map›Paper›PMID 38372444›Full record

ReviewUnited European gastroenterology journal2024

Locoregional therapies for hepatocellular carcinoma: The current status and future perspectives.

Jian-Jian Chen, Zhi-Cheng Jin, Bin-Yan Zhong, Wenzhe Fan, Wei-Hua Zhang, Biao Luo, Yu-Qing Wang, Gao-Jun Teng, Hai-Dong Zhu

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in United European gastroenterology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Relationships Among Serological Indicators andCombinatorial chemistry & high throughput screening · 2025
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jian-Jian ChenDepartment of Radiology, Center of Interventional Radiology & Vascular Surgery, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.ORCID 0000-0001-6866-6667
Zhi-Cheng JinDepartment of Radiology, Center of Interventional Radiology & Vascular Surgery, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.ORCID 0000-0002-6114-154X
Bin-Yan ZhongDepartment of Interventional Radiology, The First Affiliated Hospital of Soochow University, Soochow University, Suzhou, China.ORCID 0000-0001-9716-1211
Wenzhe FanDepartment of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Wei-Hua ZhangDepartment of Radiology, Center of Interventional Radiology & Vascular Surgery, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.
Biao LuoDepartment of Radiology, Center of Interventional Radiology & Vascular Surgery, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.
Yu-Qing WangDepartment of Radiology, Center of Interventional Radiology & Vascular Surgery, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.
Gao-Jun TengDepartment of Radiology, Center of Interventional Radiology & Vascular Surgery, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.ORCID 0000-0003-1145-0798
Hai-Dong ZhuDepartment of Radiology, Center of Interventional Radiology & Vascular Surgery, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.ORCID 0000-0003-1798-7641
Zhongda Hospital Southeast University · CNSoochow University · CNSun Yat-sen University · CN

Funding

Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, and Nanjing Life Health Science and Technology Project 202205045Jiangsu Provincial Medical Innovation Center CXZX202219National Key Research and Development Program of China 2018YFA0704100National Key Research and Development Program of China 2018YFA0704104National Natural Science Foundation of China 61821002National Natural Science Foundation of China 81827805National Natural Science Foundation of China 82130060
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers and a leading cause of cancer-related mortality. Locoregional therapies (LRTs) play a crucial role in HCC management and are selectively adopted in real-world practice across various stages. Choosing the best form of LRTs depends on technical aspects, patient clinical status and tumour characteristics. Previous studies have consistently highlighted the efficacy of combining LRTs with molecular targeted agents in HCC treatment. Recent studies propose that integrating LRTs with immune checkpoint inhibitors and molecular targeted agents could provide substantial therapeutic benefits, a notion underpinned by both basic and clinical evidence. This review summarised the current landscape of LRTs in HCC and discussed the anticipated outcomes of combinations with immunotherapy regimens.

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularLiver NeoplasmsHumansImmunotherapyTreatment OutcomeAntineoplastic Agentscombined modality therapyhepatocellular carcinomaimmune checkpoint inhibitorslocoregional therapymolecular targeted therapy

Identifiers

PMID38372444
PMCPMC10954431
OpenAlexW4391926496

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.